#USA #San Diego #Robbins LLP #Securities Fraud #Immutep Limited

Immutep Limited Under Legal Investigation for Alleged Investor Misleading

Immutep Limited, a biotechnology company specializing in cancer immunotherapies, finds itself under investigation by Robbins LLP for alleged misleading statements made to investors concerning its drug candidate's effectiveness and the status of its clinical trials. The case emphasizes the company’s troubles amid scrutiny over its trial data which could potentially lead to significant financial repercussions for shareholders.

Background of Immutep Limited

Immutep Limited, often traded on NASDAQ under the ticker symbol IMMP, focuses on developing therapies that utilize Lymphocyte Activation Gene-3 (LAG-3) to treat cancer and autoimmune diseases. Their product pipeline’s flagship includes TACTI-004, undergoing Phase III clinical trials to evaluate the efficacy of eftilagimod alfa (efti) for patients battling advanced lung cancer.

Class Action and Allegations

On May 5, 2026, a class action was filed on behalf of investors who bought shares from March 24, 2025, to March 12, 2026. The complaint alleges that during this period, the company concealed critical information about the TACTI-004 trial's status. Investors were misled into believing that the trial demonstrated strong operational progress and that interim assessments would yield positive results. However, according to court documents, internal data indicated otherwise.

Specifically, it was alleged that, contrary to external communication, Immutep executives were aware through internal analyses that the TACTI-004 trial was likely failing to achieve its primary efficacy and safety endpoints. This information was critical for keeping investors informed about the inherent risks associated with their investments.

On March 13, 2026, following a planned interim futility analysis, the company announced the independent monitoring board's recommendation to discontinue the TACTI-004 trial due to insufficient evidence of efficacy. The immediate aftermath was devastating for investors, as shares plummeted approximately 83%, from $2.76 to $0.48 per share within a single day.

What Are the Next Steps for Investors?

Investors impacted by the alleged securities fraud are encouraged to explore their legal options. Individuals who wish to step forward as lead plaintiffs are required to file their motions with the court by July 6, 2026. Acting as a lead plaintiff allows the individual to represent the interests of all shareholders involved in the class action. Importantly, it’s noted that participation is not a prerequisite to recovering any losses; investors can remain uninvolved while still being eligible for a settlement.

Robbins LLP operates on a contingency fee basis, meaning that shareholders incur no upfront costs unless a recovery is achieved. This structure seeks to ensure that shareholders can pursue justice without the additional burden of financial risk.

About Robbins LLP

Established in 2002, Robbins LLP has solidified its reputation as a leader in shareholder rights litigation. The firm is committed to assisting shareholders in recovering losses and improving corporate governance standards across various industries. With a wealth of experience in handling securities fraud cases, Robbins LLP assures investors of dedicated representation and advocacy.

For those interested in keeping abreast of this class action lawsuit or if they would like to be notified of any settlements or verdicts, subscribing to the firm’s Stock Watch service is a prudent move. This enables investors to receive crucial updates regarding any corporate malfeasance that may directly affect their investments.

In summary, amid dwindling stock prices and legal controversies, Immutep Limited's future remains uncertain, as investors weigh their options in light of the ongoing investigations and litigation.